Yifan Pharmaceutical Beheer

Beheer criteriumcontroles 4/4

De CEO Yifan Pharmaceutical is Xian Feng Cheng, benoemd in Nov2017, heeft een ambtstermijn van 7.08 jaar. bezit rechtstreeks 40.82% van de aandelen van het bedrijf, ter waarde CN¥ 5.88B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 9.4 jaar.

Belangrijke informatie

Xian Feng Cheng

Algemeen directeur

CN¥624.0k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.1yrs
Eigendom CEO	40.8%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	9.4yrs

Recente managementupdates

Recent updates

CEO

Xian Feng Cheng (56 yo)

7.1yrs

Tenure

CN¥624,000

Compensatie

Mr. Xian feng Cheng serves as the Chairman of the Board of Directors at Yifan Pharmaceutical Co., Ltd and serves as its Director since October 15, 2014 and serves as its General Manager since November 07,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Xian Feng Cheng	Chairman of the Board of Directors & GM	7.1yrs	CN¥624.00k	40.82% CN¥ 5.9b
Dawei Zhang	Financial Director	1.4yrs	CN¥240.00k	0.0032% CN¥ 456.9k
Xing Lin	Deputy GM & Director	12.1yrs	CN¥564.00k	0.063% CN¥ 9.1m
Deqi Feng	Board Secretary	no data	CN¥480.00k	0.060% CN¥ 8.7m
Ximing Li	Deputy General Manager	2.6yrs	CN¥2.74m	0.0020% CN¥ 289.7k
Yuhong Geng	Deputy General Manager	2.6yrs	CN¥1.87m	0.0032% CN¥ 462.7k
Kai Wang	Head of Accounting	no data	geen gegevens	geen gegevens
William Tan	Director of Sales Team	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002019 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xian Feng Cheng	Chairman of the Board of Directors & GM	10.2yrs	CN¥624.00k	40.82% CN¥ 5.9b
Xing Lin	Deputy GM & Director	12.1yrs	CN¥564.00k	0.063% CN¥ 9.1m
Deqi Feng	Board Secretary	8.7yrs	CN¥480.00k	0.060% CN¥ 8.7m
Jun Wang	Supervisor	6.8yrs	geen gegevens	0.000010% CN¥ 1.4k
Lian Chun Zhang	Member of the Supervisory Board	10.2yrs	CN¥234.20k	geen gegevens
Yi Qun Ye	Director	10.2yrs	CN¥480.00k	0.058% CN¥ 8.4m
Ben Yu Zhou	Director	10.2yrs	CN¥480.00k	0.032% CN¥ 4.6m
Hongquan Liu	Independent Director	4.1yrs	CN¥100.00k	geen gegevens
Xintu Lei	Independent Director	5.7yrs	CN¥100.00k	geen gegevens
Hong Cheng Gen	Independent Director	5.7yrs	CN¥100.00k	geen gegevens

9.4yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002019 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.4 jaar).

Yifan Pharmaceutical Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 06, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.03 in 3Q 2023)

Yifan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Dividend sustainability

Yifan Pharmaceutical Co., Ltd. Proposes Interim Dividend for the First Half of 2024

Second quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.039 in 2Q 2023)

Yifan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.45 loss per share (vs CN¥0.16 profit in FY 2022)

Yifan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Yifan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.032 in 3Q 2022)

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) announces an Equity Buyback for CNY 50 million worth of its shares.

Second quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.031 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.23 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.032 (vs CN¥0.069 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.031 (vs CN¥0.062 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 1Q 2021)

Less than half of directors are independent

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 06, 2022

Full year 2021 earnings released: EPS: CN¥0.23 (vs CN¥0.80 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.069 (vs CN¥0.16 in 3Q 2020)

Investor sentiment improved over the past week

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) announces an Equity Buyback for CNY 150 million worth of its shares.

Second quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.32 in 2Q 2020)

Yifan Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan A Shares for 2020, Payable on 17 May 2021

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.80 (vs CN¥0.75 in FY 2019)

Investor sentiment improved over the past week

Yifan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥16.91

New 90-day low: CN¥18.19

New 90-day low: CN¥20.47

New 90-day low: CN¥22.10

Third quarter earnings released

New 90-day low: CN¥23.93

First half earnings released

Yifan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020

New 90-day high - CN¥32.91

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd